Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.45 |
| ▸ | TUBB | P07437 | 3/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.45 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686225 | 1.00 | TUBB1 (0.56) | TUBB1PTGS1NFE2L2CYP1A1PTGS2 | |
| SCHEMBL1301189 | 0.87 | CYP1A1 (0.61) | TUBB1PTGS1NFE2L2CYP1A1PTGS2 | |
| SCHEMBL30625282 | 0.87 | CYP1A1 (0.61) | TUBB1PTGS1NFE2L2CYP1A1PTGS2 | |
| SCHEMBL2458079 | 0.87 | CYP1A1 (0.61) | TUBB1PTGS1NFE2L2CYP1A1PTGS2 | |
| SCHEMBL1301186 | 0.87 | CYP1A1 (0.61) | TUBB1PTGS1NFE2L2CYP1A1PTGS2 | |
| SCHEMBL9763361 | 0.82 | FDPS (0.48) | TUBB1PTGS1NFE2L2CYP1A1PTGS2 | |
| SCHEMBL9763371 | 0.82 | FDPS (0.48) | TUBB1PTGS1NFE2L2CYP1A1PTGS2 | |
| SCHEMBL18913776 | 0.82 | TUBB1 (0.63) | TUBB1PTGS1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3395560 | 0.81 | CYP1A1 (0.60) | TUBB1PTGS1NFE2L2CYP1A1PTGS2 | |
| SCHEMBL18913773 | 0.80 | APP (0.59) | MMP9KDM4EALDH1A1HPGDPDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1386913-B1 | PYRROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220773-B2 | Heterocylic amines used as antidiabetic or hyperglycemic agents | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040162331-A1 | Pyrrole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-08-19 | — | — | US | disclosed |
| EP-1386913-A1 | PYRROLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162331-A1 | Pyrrole derivative | SLC5A1, GLP1R, SLC5A2 | TUBB1 1963/4885PTGS1 1418/4885NFE2L2 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.